Monoclonal antibody biosimilars pose unique IP challenges

In-house sources from the biosimilar industry explain why ‘low inventive step’ and process patents keep new monoclonal antibodies off the market
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: